Lilly spends big on mirikizumab
With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.
Another chance for Lilly and Roche to take on Alzheimer's
The academic Dian-Tu study looks at anti-amyloid beta antibodies from Lilly and Roche; despite gantenerumab, hopes are being dialled back.
Novo Nordisk’s quiet entry into the year of Alzheimer’s
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
The joker in Exelixis and Bristol’s kidney cancer pack
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
The first test of Spectrum’s shift
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Acasti plays catch-up to Amarin’s Vascepa
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
Vascepa's future could hinge on next week's panel
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
First blood: Rubius approaches its big test
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Iterum’s antibiotic is far from a Sure thing
Iterum should soon find out if it has an approvable asset in the antibiotic sulopenem, but even if the group succeeds it still has a hard road ahead.
